Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
Amphotericin B
COVID-19 associated Mucormycosis
Posaconazole
Rhino-orbito-cerebral mucormycosis
diabetes mellitus
steroids
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
revised:
17
02
2022
received:
16
09
2021
accepted:
22
02
2022
pubmed:
26
2
2022
medline:
26
4
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
The second COVID-19 wave in India has been associated with an unprecedented increase in cases of COVID-19 associated mucormycosis (CAM), mainly Rhino-orbito-cerebral mucormycosis (ROCM). This retrospective cohort study was conducted at Noble hospital and Research Centre (NHRC), Pune, India, between 1 April, 2020, and 1 August, 2021, to identify CAM patients and assess their management outcomes. The primary endpoint was incidence of all-cause mortality due to CAM. 59 patients were diagnosed with CAM. Median duration from the first positive COVID-19 RT PCR test to diagnosis of CAM was 17 (IQR: 12,22) days. 90% patients were diabetic with 89% having uncontrolled sugar level (HbA1c >7%). All patients were prescribed steroids during treatment for COVID-19. 56% patients were prescribed steroids for non-hypoxemic, mild COVID-19 (irrational steroid therapy), while in 9%, steroids were prescribed in inappropriately high dose. Patients were treated with a combination of surgical debridement (94%), intravenous liposomal Amphotericin B (91%) and concomitant oral Posaconazole (95.4%). 74.6% patients were discharged after clinical and radiologic recovery while 25.4% died. On relative risk analysis, COVID-19 CT severity index ≥18 (p = .017), presence of orbital symptoms (p = .002), presence of diabetic ketoacidosis (p = .011) and cerebral involvement (p = .0004) were associated with increased risk of death. CAM is a rapidly progressive, angio-invasive, opportunistic fungal infection, which is fatal if left untreated. Combination of surgical debridement and antifungal therapy leads to clinical and radiologic improvement in majority of cases.
Sections du résumé
BACKGROUND
BACKGROUND
The second COVID-19 wave in India has been associated with an unprecedented increase in cases of COVID-19 associated mucormycosis (CAM), mainly Rhino-orbito-cerebral mucormycosis (ROCM).
METHODS
METHODS
This retrospective cohort study was conducted at Noble hospital and Research Centre (NHRC), Pune, India, between 1 April, 2020, and 1 August, 2021, to identify CAM patients and assess their management outcomes. The primary endpoint was incidence of all-cause mortality due to CAM.
RESULTS
RESULTS
59 patients were diagnosed with CAM. Median duration from the first positive COVID-19 RT PCR test to diagnosis of CAM was 17 (IQR: 12,22) days. 90% patients were diabetic with 89% having uncontrolled sugar level (HbA1c >7%). All patients were prescribed steroids during treatment for COVID-19. 56% patients were prescribed steroids for non-hypoxemic, mild COVID-19 (irrational steroid therapy), while in 9%, steroids were prescribed in inappropriately high dose. Patients were treated with a combination of surgical debridement (94%), intravenous liposomal Amphotericin B (91%) and concomitant oral Posaconazole (95.4%). 74.6% patients were discharged after clinical and radiologic recovery while 25.4% died. On relative risk analysis, COVID-19 CT severity index ≥18 (p = .017), presence of orbital symptoms (p = .002), presence of diabetic ketoacidosis (p = .011) and cerebral involvement (p = .0004) were associated with increased risk of death.
CONCLUSIONS
CONCLUSIONS
CAM is a rapidly progressive, angio-invasive, opportunistic fungal infection, which is fatal if left untreated. Combination of surgical debridement and antifungal therapy leads to clinical and radiologic improvement in majority of cases.
Identifiants
pubmed: 35212032
doi: 10.1111/myc.13435
pmc: PMC9115310
doi:
Substances chimiques
Antifungal Agents
0
Steroids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
526-540Informations de copyright
© 2022 Wiley-VCH GmbH.
Références
Mycoses. 2021 Dec;64(12):1452-1459
pubmed: 34133798
Int Forum Allergy Rhinol. 2021 Jun;11(6):1029-1030
pubmed: 33713565
Mycopathologia. 2020 Aug;185(4):599-606
pubmed: 32737747
Med J Armed Forces India. 2021 Jul;77:S289-S295
pubmed: 34334896
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Emerg Infect Dis. 2021 Sep;27(9):2349-2359
pubmed: 34087089
J Laryngol Otol. 2021 May;135(5):442-447
pubmed: 33827722
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Infect Chemother. 2013 Sep;45(3):292-8
pubmed: 24396630
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Microbiol Infect. 2011 Dec;17(12):1859-67
pubmed: 21199154
Immunol Res. 2020 Aug;68(4):213-224
pubmed: 32681497
Lancet. 2003 Nov 29;362(9398):1828-38
pubmed: 14654323
Mycopathologia. 2021 May;186(2):289-298
pubmed: 33544266
Transpl Infect Dis. 2021 Aug;23(4):e13663
pubmed: 34081817
Indian J Otolaryngol Head Neck Surg. 2019 Jun;71(2):259-265
pubmed: 31275841
Infection. 2021 Oct;49(5):1055-1060
pubmed: 33331988
Diabetes Metab Syndr. 2021 Sep-Oct;15(5):102267
pubmed: 34509790
BMJ Case Rep. 2021 Jun 24;14(6):
pubmed: 34167998
Indian J Ophthalmol. 2021 Feb;69(2):244-252
pubmed: 33463566
BMJ Case Rep. 2021 Apr 27;14(4):
pubmed: 33906877
N Engl J Med. 2020 Aug 20;383(8):789-790
pubmed: 32530585
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102146
pubmed: 34192610
Infect Dis Now. 2021 Oct;51(7):633-635
pubmed: 33527098
Indian J Ophthalmol. 2021 Jun;69(6):1563-1568
pubmed: 34011742
Front Immunol. 2020 Jun 16;11:1441
pubmed: 32612615
J Fungi (Basel). 2019 Mar 21;5(1):
pubmed: 30901907
Eur Radiol. 2020 Dec;30(12):6808-6817
pubmed: 32623505
IDCases. 2021;25:e01172
pubmed: 34075329
Indian J Ophthalmol. 2021 Jun;69(6):1627-1630
pubmed: 34011758
Clin Endosc. 2020 Nov;53(6):746-749
pubmed: 33207116
QJM. 2021 Nov 5;114(7):464-470
pubmed: 34254132
J Maxillofac Oral Surg. 2021 Sep;20(3):418-425
pubmed: 33716414
Clin Infect Dis. 2022 Apr 9;74(7):1279-1283
pubmed: 34420052
Orbit. 2021 Mar 23;:1-4
pubmed: 33752571
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
J Crit Care. 2019 Jun;51:64-70
pubmed: 30769292
Indian J Ophthalmol. 2021 Apr;69(4):1002-1004
pubmed: 33727483
Mycoses. 2021 Oct;64(10):1253-1260
pubmed: 34255907
Lancet Infect Dis. 2019 Dec;19(12):e405-e421
pubmed: 31699664
Mycoses. 2021 Oct;64(10):1238-1252
pubmed: 34096653
Ther Adv Infect Dis. 2021 Jun 18;8:20499361211027065
pubmed: 34211710
J Fungi (Basel). 2021 Feb 28;7(3):
pubmed: 33670842
Nat Metab. 2021 Feb;3(2):149-165
pubmed: 33536639
Diabetes Metab Syndr. 2021 Jul-Aug;15(4):102196
pubmed: 34246939
J Mycol Med. 2021 Jun;31(2):101125
pubmed: 33857916
Indian J Ophthalmol. 2021 Jul;69(7):1670-1692
pubmed: 34156034
Mycoses. 2022 May;65(5):526-540
pubmed: 35212032